THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 25, 2017 08:05 ET | Abeona Therapeutics Inc
Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
May 09, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
May 08, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
May 02, 2017 08:05 ET | Abeona Therapeutics Inc
--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
April 25, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, April 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona to Present At Multiple Upcoming Conferences
April 20, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
April 05, 2017 07:43 ET | Abeona Therapeutics Inc
Company CEO to Co-Chair Symposium being held on April 11th in NYC NEW YORK and CLEVELAND, April 05, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
March 31, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 31, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical  company  focused  on  developing...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
March 13, 2017 08:15 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
March 08, 2017 08:15 ET | Abeona Therapeutics Inc
Abeona’s Fourth Gene Therapy Program to Receive EMA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...